Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
de la Torre R, de Sola S, Hernandez G, Farré M, Pujol J, Rodriguez J, Espadaler JM, Langohr K, Cuenca-Royo A, Principe A, Xicota L, Janel N, Catuara-Solarz S, Sanchez-Benavides G, Bléhaut H, Dueñas-Espín I, Del Hoyo L, Benejam B, Blanco-Hinojo L, Videla S, Fitó M, Delabar JM, Dierssen M; TESDAD study group. de la Torre R, et al. Among authors: langohr k. Lancet Neurol. 2016 Jul;15(8):801-810. doi: 10.1016/S1474-4422(16)30034-5. Lancet Neurol. 2016. PMID: 27302362 Clinical Trial.
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farré M, Fitó M, Benejam B, Langohr K, Rodriguez J, Pujadas M, Bizot JC, Cuenca A, Janel N, Catuara S, Covas MI, Blehaut H, Herault Y, Delabar JM, Dierssen M. De la Torre R, et al. Among authors: langohr k. Mol Nutr Food Res. 2014 Feb;58(2):278-88. doi: 10.1002/mnfr.201300325. Epub 2013 Sep 14. Mol Nutr Food Res. 2014. PMID: 24039182 Clinical Trial.
A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome.
de la Torre R, de Sola S, Farré M, Xicota L, Cuenca-Royo A, Rodriguez J, León A, Langohr K, Gomis-González M, Hernandez G, Esteba S, Del Hoyo L, Sánchez-Gutiérrez J, Cortés MJ, Ozaita A, Espadaler JM, Novell R, Martínez-Leal R, Milá M, Dierssen M; TESXF Study Group. de la Torre R, et al. Among authors: langohr k. Clin Nutr. 2020 Feb;39(2):378-387. doi: 10.1016/j.clnu.2019.02.028. Epub 2019 Mar 25. Clin Nutr. 2020. PMID: 30962103 Clinical Trial.
A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials.
de Sola S, de la Torre R, Sánchez-Benavides G, Benejam B, Cuenca-Royo A, Del Hoyo L, Rodríguez J, Catuara-Solarz S, Sanchez-Gutierrez J, Dueñas-Espin I, Hernandez G, Peña-Casanova J, Langohr K, Videla S, Blehaut H, Farre M, Dierssen M; TESDAD Study Group. de Sola S, et al. Among authors: langohr k. Front Psychol. 2015 Jun 4;6:708. doi: 10.3389/fpsyg.2015.00708. eCollection 2015. Front Psychol. 2015. PMID: 26089807 Free PMC article.
Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma Aβ42 Concentrations in Down Syndrome Young Adults.
Hoyo LD, Xicota L, Sánchez-Benavides G, Cuenca-Royo A, de Sola S, Langohr K, Fagundo AB, Farré M, Dierssen M, de la Torre R. Hoyo LD, et al. Among authors: langohr k. Front Behav Neurosci. 2015 Nov 18;9:301. doi: 10.3389/fnbeh.2015.00301. eCollection 2015. Front Behav Neurosci. 2015. PMID: 26635555 Free PMC article.
Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome.
Catuara-Solarz S, Espinosa-Carrasco J, Erb I, Langohr K, Notredame C, Gonzalez JR, Dierssen M. Catuara-Solarz S, et al. Among authors: langohr k. Front Behav Neurosci. 2015 Dec 11;9:330. doi: 10.3389/fnbeh.2015.00330. eCollection 2015. Front Behav Neurosci. 2015. PMID: 26696850 Free PMC article.
VNTR-DAT1 and COMTVal158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome.
Del Hoyo L, Xicota L, Langohr K, Sánchez-Benavides G, de Sola S, Cuenca-Royo A, Rodriguez J, Rodríguez-Morató J, Farré M, Dierssen M, de la Torre R; TESDAD Study Group. Del Hoyo L, et al. Among authors: langohr k. Front Behav Neurosci. 2016 Oct 17;10:193. doi: 10.3389/fnbeh.2016.00193. eCollection 2016. Front Behav Neurosci. 2016. PMID: 27799900 Free PMC article.
Combined Treatment With Environmental Enrichment and (-)-Epigallocatechin-3-Gallate Ameliorates Learning Deficits and Hippocampal Alterations in a Mouse Model of Down Syndrome.
Catuara-Solarz S, Espinosa-Carrasco J, Erb I, Langohr K, Gonzalez JR, Notredame C, Dierssen M. Catuara-Solarz S, et al. Among authors: langohr k. eNeuro. 2016 Nov 8;3(5):ENEURO.0103-16.2016. doi: 10.1523/ENEURO.0103-16.2016. eCollection 2016 Sep-Oct. eNeuro. 2016. PMID: 27844057 Free PMC article.
Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study).
Cieuta-Walti C, Cuenca-Royo A, Langohr K, Rakic C, López-Vílchez MÁ, Lirio J, González-Lamuño Leguina D, González TB, García JG, Roure MR, Aldea-Perona A, Forcano L, Gomis-Gonzalez M, Cés SV, Lacaille F, Ravel A, Mircher C, Walti H, Janel N, Dairou J, Lévy M, Durand S, Dierssen M, Sacco S, Fornell RT; PERSEUS Study Group. Cieuta-Walti C, et al. Among authors: langohr k. Genet Med. 2022 Oct;24(10):2004-2013. doi: 10.1016/j.gim.2022.06.011. Epub 2022 Aug 11. Genet Med. 2022. PMID: 35951014 Free article. Clinical Trial.
94 results